ChiCTR2200055862 版本V1.6 版本创建时间2022/08/25 08:44:50 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200055862 

最近更新日期:

Date of Last Refreshed on:

2022-08-25 08:42:53 

注册时间:

Date of Registration:

2022-01-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

高三酰甘油血症性急性胰腺炎与肠道菌群的关系初探

Public title:

Preliminary study on the relationship between intestinal flora and Hypertriglyceridemia-induced acute pancreatitis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

高三酰甘油血症性急性胰腺炎与肠道菌群的关系初探

Scientific title:

Preliminary study on the relationship between intestinal flora and Hypertriglyceridemia-induced acute pancreatitis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

郭清清 

研究负责人:

郭清清 

Applicant:

Guo Qingqing 

Study leader:

Guo Qingqing 

申请注册联系人电话:

Applicant telephone:

+86 15280160322

研究负责人电话:

Study leader's
telephone:

+86 15280160322

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

guoqq7@163.com

研究负责人电子邮件:

Study leader's E-mail:

guoqq7@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市茶中路20号

研究负责人通讯地址:

福建省福州市茶中路20号

Applicant address:

20 Chazhong Road, Fuzhou, Fujian

Study leader's address:

20 Chazhong Road, Fuzhou, Fujian

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福建医科大学附属第一医院

Applicant's institution:

the First Affiliated Hospital of Fujian Medical University

研究负责人所在单位:

福建医科大学附属第一医院

Affiliation of the Leader:

the First Affiliated Hospital of Fujian Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

MRCTA, ECFAH of FMU 【2021】242

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建医科大学附属第一医院医学伦理委员会医学研究与临床技术应用分会

Name of the ethic committee:

Branch for Medical Research and Clinical Technology Application, Ethics Committee of the First Affiliated Hospital of Fujian Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-06-18 00:00:00

伦理委员会联系人:

王柠

Contact Name of the ethic committee:

Wang Ning

伦理委员会联系地址:

福建省福州市茶中路20号

Contact Address of the ethic committee:

20 Chazhong Road, Fuzhou, Fujian

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

福建医科大学附属第一医院

Primary sponsor:

the First Affiliated Hospital of Fujian Medical University

研究实施负责(组长)单位地址:

福建省福州市茶中路20号

Primary sponsor's address:

20 Chazhong Road, Fuzhou, Fujian

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建省

市(区县):

福州

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建医科大学附属第一医院

具体地址:

茶中路20号

Institution
hospital:

The First Affiliated Hospital of Fujian Medical University

Address:

20 Chazhong Road

经费或物资来源:

福建医科大学

Source(s) of funding:

Fujian Medical University

研究疾病:

高三酰甘油血症性急性胰腺炎  

Target disease:

Hypertriglyceridemia-induced acute pancreatitis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

揭示高脂血症性胰腺炎和单纯高脂血症患者之间,肠道菌群多样性及丰度的差异。  

Objectives of Study:

To reveal the difference of intestinal flora diversity between patients with hyperlipidemia pancreatitis and patients with hyperlipidemia alone.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 符合2019年《中国急性胰腺炎诊治指南》对高脂性胰腺炎诊断标准;
2. 符合原发性高脂血症诊断标准。

Inclusion criteria

1. It conforms to the diagnostic criteria for hyperlipidemia pancreatitis in the 2019 Chinese Guidelines for the Diagnosis and Treatment of Acute Pancreatitis;
2. It conforms to the diagnostic criteria of primary hyperlipidemia.

排除标准:

1. 其他原因引起的胰腺炎;
2. 正在参加或3个月内参加其他临床试验的病例;
3. 近2周口服益生菌、益生元、抗生素等者。

Exclusion criteria:

1. Pancreatitis from other causes;
2. Those who are participating in or participating in other clinical trials within 3 months;
3. Those who have taken oral probiotics, prebiotics, antibiotics, ect. in the past 2 weeks.

研究实施时间:

Study execute time:

From 2022-01-15 00:00:00 To 2024-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-21 00:00:00 To 2022-12-31 00:00:00

干预措施:

Interventions:

组别:

观察组(高脂血症性急性胰腺炎)

样本量:

60

Group:

Observation group (Hypertriglyceridemia-induced acute pancreatitis)

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

对照组(高脂血症)

样本量:

60

Group:

Control group (hyperlipidemia)

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建省 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

福建医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Fujian Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肠道内菌群多样性及丰度

指标类型:

主要指标

Outcome:

Intestinal flora diversity and abundance

Type:

Primary indicator

测量时间点:

测量方法:

16s-rRNA二代测序

Measure time point of outcome:

Measure method:

The next-generation sequencing of 16s-rRNA

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

开放标签方法

Randomization Procedure (please state who generates the random number sequence and by what method):

open label approach

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

以论文形式发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Published as a paper

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

case record form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-01-21 08:40:43